Management of Apixaban-Induced Thrombocytopenia

General Management Principles

The American College of Cardiology recommends continuing apixaban at full therapeutic dose if platelet count is ≥50 × 10⁹/L without platelet transfusion support 1, 2
For patients with platelet counts 25-50 × 10⁹/L, the American College of Cardiology suggests reducing apixaban dose to 50% of therapeutic dose or switching to prophylactic-dose LMWH 1, 2
For patients with platelet counts <25 × 10⁹/L, temporary discontinuation of anticoagulation is recommended 1, 2
Resume full-dose anticoagulation when platelet count rises >50 × 10⁹/L without transfusion support, in the absence of other contraindications 1, 2

Immediately discontinue all heparin products (unfractionated heparin, LMWH, heparin flushes) in patients with HIT 3, 4, 5
For severe HIT with life-threatening or limb-threatening thrombosis, prefer parenteral non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, or fondaparinux) over DOACs 3, 4, 6
For less severe HIT without life-threatening thrombosis, apixaban may be considered as an alternative option 3, 4, 5
Rivaroxaban is the most studied DOAC for HIT, with a recommended dose of 15 mg twice daily until day 21 or complete platelet recovery, then 20 mg daily for at least one month 3, 4, 5

Confirm HIT diagnosis with laboratory testing (PF4/heparin antibody ELISA and serotonin release assay) before attributing thrombocytopenia to HIT rather than apixaban 3, 4, 5
DOACs should not replace confirmatory HIT testing: even when using apixaban for suspected HIT, complete the diagnostic workup 3, 4, 5

For bleeding on apixaban, stop apixaban and consider andexanet alfa (400-800 mg IV bolus followed by infusion) for reversal 7